KEYTRUDA QLEX is the first and only subcutaneously administered immune checkpoint inhibitor that can be given by a health care provider in as little as one minute RAHWAY, N.J.--(BUSINESS WIRE)-- Merck ...

Health minister hopes a key injectable cancer drug will be available in all five trusts "as soon as possible".

A new mRNA melanoma vaccine from Merck and Moderna showed sustained benefits over five years, cutting the risk of cancer ...

Positive opinion also granted for KEYTRUDA as part of a perioperative regimen for the treatment of certain adult patients with resectable locally advanced head and neck squamous cell carcinoma ...

The U.S. Food and Drug Administration (FDA) has approved a new way to give pembrolizumab (brand name: Keytruda), one of the most widely used immunotherapy treatments for cancer. For the first time, ...

Since 2015, NHS patients have received the world's best-selling drug through a drip – or intravenous infusion – which can take more than an hour to administer in hospital. NHS England says the new ...

Keytruda, a Merck cancer immunotherapy that has become the world’s top-selling medication, is administered as an intravenous infusion over the course of 30 minutes. The pharmaceutical giant now has ...

A vaccine and a drug that harness the immune system to attack cancer cells, has cut the risk of skin cancer recurrence and ...

At a median 5-year (60.3 months) planned follow-up of the Phase 2b KEYNOTE-942/mRNA-4157-P201 study, intismeran autogene in combination with KEYTRUDA demonstrated a 49% reduction in the risk of ...

Vast numbers of NHS patients and staff throughout England are expected to reap the benefits of the injection, reports the Mirror. Dr Hilary explained: "It is replacing an intraven ...